Endo grabs Aspen branded, generic meds; Ironwood, Actavis sponsor IBS survey;

> Endo International ($ENDP) snapped up a portfolio of branded and generic products from Aspen, expanding its presence in that company's home country of South Africa. Release

> Ironwood Pharmaceuticals and Actavis ($ACT) are sponsoring a broad survey of patients with irritable bowel syndrome, under the auspices of the American Gastroenterological Association. Release

> Spain's Almirall racked up €217 million in first-quarter sales, including a milestone payment from AstraZeneca ($AZN) stemming from a respiratory drug deal last year. Release

> Roche ($RHHBY) will roll out new pivotal data on its cancer drug Gazyva in non-Hodgkin's lymphoma and the as-yet-unapproved ALK inhibitor alectinib in non-small-cell lung cancer at the American Society for Clinical Oncology meeting later this month. Release

And Finally... The New Yorker returned to McAllen, TX, to find that the notoriously high-spending market has cut its health expenses substantially. Report

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

To take on AbbVie’s megablockbuster Humira, drugmakers need compelling data for physicians. Could Eli Lilly's Taltz be up to the challenge?

Why did GSK tweak its strict ethics measures for sales reps? When it first nixed incentive-based compensation, it thought other pharmas would, too.